UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (973) 973
science & technology (874) 874
life sciences & biomedicine (866) 866
myeloablative agonists - therapeutic use (759) 759
male (701) 701
female (694) 694
hematology (678) 678
transplantation (623) 623
adult (567) 567
middle aged (544) 544
immunology (463) 463
transplantation conditioning - methods (434) 434
transplantation, homologous (405) 405
adolescent (386) 386
hematopoietic stem cells (340) 340
hematopoietic stem cell transplantation (336) 336
stem cells (332) 332
aged (319) 319
treatment outcome (316) 316
hematology, oncology and palliative medicine (315) 315
survival analysis (285) 285
oncology (277) 277
retrospective studies (272) 272
child (266) 266
biological and medical sciences (236) 236
medical sciences (236) 236
transplantation conditioning (232) 232
hematopoietic stem cell transplantation - methods (219) 219
child, preschool (218) 218
myeloablative agonists - administration & dosage (182) 182
young adult (182) 182
vidarabine - analogs & derivatives (178) 178
graft vs host disease - prevention & control (177) 177
recurrence (170) 170
hematopoietic stem cell transplantation - adverse effects (167) 167
myeloablative agonists - adverse effects (163) 163
analysis (162) 162
infant (158) 158
hematologic neoplasms - therapy (153) 153
graft vs host disease - mortality (144) 144
health aspects (142) 142
care and treatment (141) 141
transplantation, autologous (138) 138
bone marrow (137) 137
disease-free survival (136) 136
graft vs host disease - immunology (131) 131
vidarabine - therapeutic use (128) 128
mortality (127) 127
transplantation conditioning - adverse effects (126) 126
immunosuppressive agents - therapeutic use (122) 122
risk factors (122) 122
cancer (120) 120
biophysics (119) 119
stem cell transplantation (117) 117
prognosis (116) 116
busulfan - therapeutic use (112) 112
leukemia, myeloid, acute - therapy (111) 111
hematologic and hematopoietic diseases (109) 109
melphalan - therapeutic use (108) 108
graft vs host disease - pathology (106) 106
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (102) 102
transfusions. complications. transfusion reactions. cell and gene therapy (102) 102
bone marrow, stem cells transplantation. graft versus host reaction (101) 101
cyclophosphamide - therapeutic use (100) 100
busulfan - administration & dosage (98) 98
follow-up studies (96) 96
unrelated donors (96) 96
hematologic neoplasms - immunology (95) 95
graft vs host disease - etiology (93) 93
histocompatibility testing (93) 93
hematologic neoplasms - mortality (92) 92
antineoplastic combined chemotherapy protocols - therapeutic use (91) 91
chemotherapy (91) 91
prospective studies (90) 90
leukemia (89) 89
remission induction (87) 87
busulfan (85) 85
research (83) 83
acute disease (82) 82
survival rate (82) 82
siblings (81) 81
hematologic neoplasms - pathology (77) 77
pediatrics (77) 77
combined modality therapy (76) 76
patient outcomes (76) 76
graft survival (75) 75
hematopoietic stem cell transplantation - mortality (74) 74
time factors (74) 74
whole-body irradiation (69) 69
dosage and administration (68) 68
abridged index medicus (67) 67
bone marrow transplantation (66) 66
leukemia, myeloid, acute - mortality (66) 66
multiple myeloma - therapy (66) 66
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (65) 65
multiple myeloma (63) 63
cyclophosphamide (62) 62
t cells (61) 61
melphalan - administration & dosage (59) 59
medical colleges (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (978) 978
French (5) 5
Russian (3) 3
Spanish (3) 3
Chinese (1) 1
Czech (1) 1
Danish (1) 1
German (1) 1
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 0923-7534, 05/2011, Volume 22, Issue 5, pp. 1221 - 1227
Journal Article
Annals of oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2970 - 2976
total-lung irradiation | lung metastases | Ewing's sarcoma | high-dose chemotherapy | Lung metastases | Total-lung irradiation | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pneumology | Myeloablative Agonists - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Bone Neoplasms - secondary | Child, Preschool | Lung Neoplasms - radiotherapy | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Young Adult | Lung Neoplasms - secondary | Neoplasm Metastasis - drug therapy | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Neoplasm Metastasis - radiotherapy | Etoposide - therapeutic use | Combined Modality Therapy | Lung Neoplasms - therapy | Sarcoma, Ewing - drug therapy | Sarcoma, Ewing - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Sarcoma, Ewing - radiotherapy | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | total-lung | Klinisk medicin | Cancer and Oncology | irradiation | Cancer och onkologi
Journal Article
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 02/2019, Volume 54, Issue 2, pp. 204 - 211
Journal Article
American journal of hematology, ISSN 0361-8609, 10/2018, Volume 93, Issue 10, pp. 1211 - 1219
Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Confidence Intervals | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Humans | Middle Aged | Drug Evaluation | Male | Living Donors | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Allografts | Bone Marrow Transplantation | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Proportional Hazards Models | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Thiotepa - adverse effects | Cyclophosphamide | Transplantation | Comparative analysis | Thiotepa | Stem cells | Fludarabine | Cord blood | Donors | Transplants & implants | Myeloid leukemia | Leukemia | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 4, pp. 723 - 730
Hematology, Oncology and Palliative Medicine | Cidofovir | BK virus | Hemorrhagic cystitis | Hematopoietic stem cell transplantation | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Polyomavirus Infections - immunology | Cytosine - analogs & derivatives | Polyomavirus Infections - etiology | BK Virus - drug effects | Hematologic Neoplasms - mortality | Humans | Middle Aged | Hemorrhage - mortality | Cystitis - immunology | Male | Hematologic Neoplasms - pathology | Transplantation, Homologous | Hemorrhage - etiology | Hematopoietic Stem Cell Transplantation - adverse effects | Tumor Virus Infections - immunology | Tumor Virus Infections - therapy | Adult | Female | Cytosine - therapeutic use | Retrospective Studies | Cystitis - etiology | Glomerular Filtration Rate | Drug Administration Schedule | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Hemorrhage - therapy | Hemorrhage - immunology | Cystitis - therapy | Graft Survival | Tumor Virus Infections - mortality | Cystitis - mortality | Polyomavirus Infections - mortality | Polyomavirus Infections - therapy | Survival Analysis | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Tumor Virus Infections - etiology | Viral Load - drug effects | BK Virus - physiology | Care and treatment | Cystitis | Hematopoietic stem cells | Stem cells | Medical research | Leptin | Medicine, Experimental | Epstein-Barr virus | Index Medicus | Life Sciences | Cancer
Journal Article
British journal of haematology, ISSN 0007-1048, 10/2011, Volume 155, Issue 2, pp. 218 - 234
paediatrics | graft‐versus‐host disease | immune | cord blood transplantation | immunology | Graft-versus-host disease | Immunology | Immune | Paediatrics | Cord blood transplantation | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Myeloablative Agonists - therapeutic use | Recombinant Proteins - therapeutic use | Whole-Body Irradiation | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Neoplasms - surgery | Humans | Child, Preschool | Male | Antibiotic Prophylaxis | Melphalan - therapeutic use | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Busulfan - administration & dosage | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Antibodies, Monoclonal, Humanized - administration & dosage | Female | Leukocyte Count | Retrospective Studies | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Busulfan - therapeutic use | T-Lymphocytes | Neutrophils | Graft Survival | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Cord Blood Stem Cell Transplantation - methods | Melphalan - administration & dosage | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Antilymphocyte Serum | Genetic Diseases, Inborn - surgery | Vidarabine - administration & dosage | Pediatrics | Immunoglobulins | Immunotherapy | Stem cells | Transplantation | Comparative analysis | Health aspects | Index Medicus
Journal Article